MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1101/2025.07.17.664511

Медицинская библиотека · bioRxiv : the preprint server for biology · 2025

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against Plasmodium falciparum via Dual Inhibition of PfArk1 and Hemozoin Formation.

Wicht Kathryn J, Woodland John G, Garnie Larnelle F, Langeveld Henrico, Taylor Dale, Godoy Luiz C, Pasaje Charisse Flerida A, de Souza Mariana Laureano, Siqueira-Neto Jair L, Ghidelli-Disse Sonja, Lafuente-Monasterio Maria Jose, Gamo Francisco-Javier, Coertzen Dina, Reader Janette, van der Watt Mariëtte, Bridgford Jessica L, Girling Gareth, Coyle Rachael, Scheurer Christian, Wittlin Sergio, Lee Marcus C S, Voss Till S, Winzeler Elizabeth A, Fidock David A, Niles Jacquin C, Birkholtz Lyn-Marié, Coulson Lauren B, Chibale Kelly

СтатьяПрепринтПеревод в очереди

Аннотация

The high burden of malaria and growing resistance to frontline antimalarials demand new drugs with reduced propensities for generating resistance. An attractive approach to identifying chemical hits as starting points for antimalarial drug discovery involves the repositioning and chemical optimization of compounds used in other disease areas that are active against the human malaria parasite Plasmodium falciparum. Here we show that the human checkpoint kinase 1 (Chk1) inhibitor CHIR-124 is active in vitro against both drug-sensitive and drug-resistant asexual blood stage parasites and competitively binds to several Plasmodium kinases, including P. falciparum aurora-related kinase-1 (PfArk1). The compound also shows moderate activity against both the liver and gametocyte forms of the parasite. Further target investigation for CHIR-124 via conditional knockdown experiments confirmed that PfArk1 is implicated in its parasiticidal activity. Notably, CHIR-124 also inhibits β-hematin (synthetic hemozoin) formation and causes a dose-dependent increase in free heme that correlates with inhibition of parasite growth. These findings suggest that polypharmacology is involved in the activity of CHIR-124 against P. falciparum via the dual inhibition of Plasmodium PfArk1 and hemozoin formation, both essential for parasite proliferation. This is further supported by in vitro drug combination experiments, morphological studies and resistance generation attempts. This study demonstrates the feasibility of designing dual Plasmodium kinase/hemozoin formation inhibitors active against resistant strains with decreased resistance risks in the fight against malaria.

Для цитирования: Wicht Kathryn J, Woodland John G, Garnie Larnelle F, Langeveld Henrico, Taylor Dale, Godoy Luiz C, Pasaje Charisse Flerida A, de Souza Mariana Laureano, Siqueira-Neto Jair L, Ghidelli-Disse Sonja, Lafuente-Monasterio Maria Jose, Gamo Francisco-Javier, Coertzen Dina, Reader Janette, van der Watt Mariëtte, Bridgford Jessica L, Girling Gareth, Coyle Rachael, Scheurer Christian, Wittlin Sergio, Lee Marcus C S, Voss Till S, Winzeler Elizabeth A, Fidock David A, Niles Jacquin C, Birkholtz Lyn-Marié, Coulson Lauren B, Chibale Kelly. The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against Plasmodium falciparum via Dual Inhibition of PfArk1 and Hemozoin Formation.. bioRxiv : the preprint server for biology. 2025. DOI: 10.1101/2025.07.17.664511.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.